Why does null hypothesis testing matter for EUS-B target validation?

Null hypothesis testing in EUS-B-guided biopsies ensures that observed differences in tissue characteristics or biomarker expression are statistically significant, supporting robust target validation. This reduces the risk of false positives in early discovery and informs confident advancement decisions. Reliable statistical analysis underpins the credibility of findings from challenging anatomical sites.

How does independent variable isolation fit EUS-B biopsy workflows?

Isolating independent variables, such as anatomical site or lesion type, during EUS-B-guided sampling allows researchers to attribute observed effects directly to specific conditions. This clarity supports mechanistic de-risking and enhances the interpretability of downstream molecular or cellular analyses. Controlled sampling strengthens the translational value of biopsy data.

What do quantitative dependent variable measurements enable in EUS-B?

Quantitative measurements, such as diagnostic hit rates and lesion-specific yields, enable objective comparison of EUS-B performance across anatomical sites. These outputs inform assay development, protocol optimization, and cross-study reproducibility. Quantitative data also support portfolio-level decisions on sampling strategies and resource allocation.

Why are replication requirements critical for EUS-B cross-functional collaboration?

Replication of EUS-B-guided biopsy results across operators and sites ensures that findings are robust and generalizable, facilitating collaboration between discovery, translational, and clinical teams. Standardized protocols and reproducible outcomes build confidence in the method's utility for multi-center studies. This reliability is essential for enterprise-scale R&D integration.

What statistical analysis capabilities are required before EUS-B implementation?

Robust statistical analysis is needed to evaluate diagnostic success rates, complication frequencies, and sample quality metrics in EUS-B procedures. These analyses guide protocol refinement, training needs, and risk assessment prior to broader implementation. Data-driven decision-making ensures that EUS-B adoption aligns with enterprise R&D objectives.

食道における気管支内超音波検査のための内視鏡の使用

1.5K views

04:35 min

November 21st, 2023

10.3791/65741-v

November 21st, 2023

1.5K views

Mohammad A. Issa¹ , Paul F. Clementsen² , Christian B. Laursen³^,⁴ , Peter Vilmann⁵^,⁶ , Ida S. Christiansen⁷ , Laurence Crombag⁸ , Uffe Bodtger¹^,⁹

¹Pulmonary Research Unit (PLUZ), Department of Respiratory Medicine, Zealand University Hospital, ²Copenhagen Academy for Medical Education and Simulation (CAMES), Copenhagen University Hospital, Rigshospitalet, ³Department of Respiratory Medicine, Odense University Hospital, ⁴Odense Respiratory Research Unit (ODIN), Department of Clinical Research, University of Southern Denmark, ⁵Department of Surgery, Copenhagen University Hospital, ⁶Department of Clinical Medicine, University of Copenhagen, ⁷Department of Pathology, Copenhagen University Hospital, Rigshospitalet, ⁸Department of Respiratory Medicine, University Medical Center, University of Amsterdam, ⁹Institute for Regional Health Research, University of Southern Denmark

経食道超音波 (EUS-B) は、食道と胃のエコー内気管支鏡 (EBUS) を使用した安全で実行可能な手順です。6つの解剖学的ランドマークを特定した後、追加の構造を特定して生検することができ、その後の診断セッションを節約できます。したがって、EUS-Bは、肺がんやその他の疾患の診断における気管支鏡検査とEBUSの理想的な継続です。